Peptide Comparison
Epitalon vs Cardiogen
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Epitalon has stronger documented evidence (Russia-Clinical + Animal Studies) than Cardiogen (Russian Research) while both occupy the khavinson class. When clinical-evidence tier is the deciding factor, Epitalon is the safer pick. Cardiogen may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Epitalon | Cardiogen | |
|---|---|---|
| Class | Khavinson pineal tetrapeptide; longevity peptide | Khavinson short peptide bioregulator |
| Drug class | Longevity | Tissue Repair |
| Mechanism | Activates telomerase gene expression; modulates pineal function and melatonin secretion | Tissue-specific gene expression modulation in cardiomyocytes |
| Route | SC / Oral | Oral |
| Half-life | ~20 min | Short (minutes) |
| Dosage (research) | 5 mg SC daily for 10-20 day cycles 2x yearly (Khavinson Russian gerontology starting dose, range up to 10 mg/day per published protocols) | Oral capsule 1-2x daily |
| Evidence tier | Russia-Clinical + Animal Studies | Russian Research |
| Research depth | 176 indexed | 89 indexed |
| Availability | Research | Research |
| Reported risks | Limited Western trials; Russian-origin data | Limited Western evidence; no regulatory approval |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Epitalon or Cardiogen?
Epitalon has stronger documented evidence (Russia-Clinical + Animal Studies) than Cardiogen (Russian Research) while both occupy the khavinson class. When clinical-evidence tier is the deciding factor, Epitalon is the safer pick. Cardiogen may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between Epitalon and Cardiogen?
Epitalon is classed as Khavinson pineal tetrapeptide; longevity peptide; Cardiogen is classed as Khavinson short peptide bioregulator. Reported mechanism: Epitalon, Activates telomerase gene expression; modulates pineal function and melatonin secretion; Cardiogen, Tissue-specific gene expression modulation in cardiomyocytes. Reported half-life: Epitalon, ~20 min; Cardiogen, Short (minutes). Routes in published studies: Epitalon, SC / Oral; Cardiogen, Oral.
Which has stronger evidence, Epitalon or Cardiogen?
Epitalon has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Epitalon is graded Russia-Clinical + Animal Studies, with 7 cited sources on its reference page and 176 indexed studies. Cardiogen is graded Russian Research, with 2 cited sources on its reference page and 89 indexed studies.
Which is more accessible, Epitalon or Cardiogen?
Neither Epitalon nor Cardiogen is an FDA-approved drug. Catalog status: Epitalon, Research; Cardiogen, Research. Epitalon's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn.
Are Epitalon and Cardiogen ever combined?
Epitalon and Cardiogen appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…